Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Pharm Anal ; 12(2): 243-252, 2022 Apr.
Article in English | MEDLINE | ID: mdl-35582400

ABSTRACT

Viscum coloratum (Kom.) Nakai is a well-known medicinal hemiparasite widely distributed in Asia. The synthesis and accumulation of its metabolites are affected by both environmental factors and the host plants, while the latter of which is usually overlooked. The purpose of this study was to comprehensively evaluate the effects of host and habitat on the metabolites in V. coloratum through multiple chemical and biological approaches. The metabolite profile of V. coloratum harvested from three different host plants in two habitats were determined by multiple chemical methods including high-performance liquid chromatography-ultraviolet (HPLC-UV), gas chromatography-flame ionization detector (GC-FID) and ultra-performance liquid chromatography quadrupole time of flight mass spectrometry (UPLC-QTOF/MS). The differences in antioxidant efficacy of V. coloratum were determined based on multiple in vitro models. The multivariate statistical analysis and data fusion strategy were applied to analyze the differences in metabolite profile and antioxidant activity of V. coloratum. Results indicated that the metabolite profile obtained by various chemical approaches was simultaneously affected by host and environment factors, and the environment plays a key role. Meanwhile, three main differential metabolites between two environment groups were identified. The results of antioxidant assay indicated that the environment has greater effects on the biological activity of V. coloratum than the host. Therefore, we conclude that the integration of various chemical and biological approaches combined with multivariate statistical and data fusion analysis, which can determine the influences of host plant and habitat on the metabolites, is a powerful strategy to control the quality of semi-parasitic herbal medicine.

2.
J Pharm Biomed Anal ; 207: 114432, 2022 Jan 05.
Article in English | MEDLINE | ID: mdl-34715580

ABSTRACT

The traditional Chinese medicine syndrome "Kidney yang deficiency" is a kind of chronic kidney disease. With the development of society, the incidence of chronic kidney disease is increasing year by year, which also brings great economic pressure to people. Semen Cuscutae is an important traditional Chinese medicine to tonify liver and kidney, mainly used to tonify deficiency of liver and kidney, spleen and kidney deficiency and diarrhea. Although there are a lot of research at the molecular and cellular level to study the Semen Cuscutae on the treatment of Kidney yang deficiency syndrome, but there's no comprehensive research complete with metabolomics method from plasma, feces and urine metabolites aspects. The purpose of this study is to find the potential differential biomarkers of the Kidney yang deficiency model and blank group rats in plasma, urine and feces, and to investigate the mechanism of Semen Cuscutae in the treatment of Kidney yang deficiency syndrome. In this study, ultra high-performance liquid chromatography-quadrupole time-of-flight Mass Spectrometry (UPLC-QTOF/MS) was used to identify potential biomarkers. Through the analysis of metabolic profiles of plasma, urine, and feces, as well as multivariate statistical analysis and pathway analysis, the therapeutic mechanism of Semen Cuscutae for Kidney yang deficiency syndrome was described. The results showed that there were 69 differential metabolites in plasma, 93 differential metabolites in feces and 62 differential metabolites in urine, and the changes of the levels of these biomarkers showed that Semen Cuscutae had a good therapeutic effect on Kidney yang deficiency syndrome. Through the analysis of the channel, the metabolite changes mainly affected the steroid hormone biosynthesis, arachidonic acid metabolism, primary bile acid biosynthesis, sheath lipid metabolism and biosynthesis of tyrosine, phenylalanine metabolism, retinol metabolism,taurine and hypotaurine metabolism, lysine degradation and vitamin B6 metabolism, tryptophan metabolism, terpenoid backbone biosynthesis and starch and sucrose metabolism. Therefore, the results suggested that Semen Cuscutae could exert a good therapeutic effect by reversing the levels of some biomarkers.


Subject(s)
Metabolomics , Semen , Animals , Chromatography, High Pressure Liquid , Kidney , Mass Spectrometry , Rats
3.
Nat Prod Res ; 34(10): 1446-1451, 2020 May.
Article in English | MEDLINE | ID: mdl-30375249

ABSTRACT

Semen Cuscutae, which mainly consisted of flavonoids, is a traditional Chinese herbal medicine and used for nourishing the liver and kidneys. The aim of this study was to develop a sensitive and selective UPLC-MS/MS method for simultaneous separation and determination of six main active renoprotective components of Hyperoside, Astragalin, Isoquercitrin, Quercitrin, Quercetin, and Kaempferol from Semen Cuscutae in rat plasma, and to reveal the pharmacokinetic differences between normal and kidney deficient rats. The validated method has been successfully applied to comparing pharmacokinetic profiles of the six analytes in rat plasma. The results indicated that there was significant difference in pharmacokinetic parameters of the six analytes between two groups, while absorptions in kidney deficient group were significantly lower than those in normal group. This study would be helpful for evaluating the Semen Cuscutae as renoprotective drug candidates for pre-clinical and clinical research.


Subject(s)
Chromatography, High Pressure Liquid/methods , Drugs, Chinese Herbal/pharmacokinetics , Flavonoids/blood , Flavonoids/pharmacokinetics , Tandem Mass Spectrometry/methods , Animals , Cuscuta/chemistry , Drugs, Chinese Herbal/analysis , Drugs, Chinese Herbal/chemistry , Female , Flavonoids/isolation & purification , Kidney/drug effects , Kidney/physiopathology , Limit of Detection , Quercetin/analogs & derivatives , Quercetin/blood , Rats, Wistar , Reproducibility of Results , Sensitivity and Specificity
4.
J Sep Sci ; 38(3): 530-40, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25402838

ABSTRACT

A simple, specific, and sensitive ultra high performance liquid chromatography with tandem mass spectrometry method was developed and validated for the simultaneous quantification of nine compounds including a new compound, rhamnazin-3-Ο-ß-D-(6″-ß-hydroxy-ß-methyglutaryl)-ß-D-glucoside-4'-Ο-ß-D-glucoside, in rat plasma using baicalin as an internal standard. The plasma samples were pretreated and extracted by protein precipitation with 0.2% formic acid in acetonitrile. The analytes were separated on a Thermo Syncronis C18 column by gradient elution with a mobile phase consisting of acetonitrile and 0.1% aqueous formic acid at a flow rate of 0.25 mL/min. The detection of the analytes was performed on an electrospray ionization interface operating in positive-ion and multiple reaction monitoring acquisition modes. The calibration curves of these analytes showed good linearity (r > 0.99) within the test ranges. The lower limit of quantification ranged from 0.4 to 20.1 ng/mL for the analytes. The intra- and interday precision and accuracy were all within ±15%, and the recoveries were higher than 80.0%. The validated method was successfully applied to a pharmacokinetic study of the nine flavonoids after administration of the Viscum coloratum extracts by intravenous injection.


Subject(s)
Flavonoids/blood , Flavonoids/pharmacokinetics , Plant Extracts/chemistry , Viscum/chemistry , Animals , Chromatography, High Pressure Liquid , Flavonoids/administration & dosage , Flavonoids/chemistry , Injections, Intravenous , Male , Molecular Structure , Plant Extracts/administration & dosage , Plant Extracts/blood , Plant Extracts/pharmacokinetics , Rats , Rats, Wistar , Tandem Mass Spectrometry
5.
World J Hepatol ; 4(12): 389-93, 2012 Dec 27.
Article in English | MEDLINE | ID: mdl-23355917

ABSTRACT

AIM: To study the effect of rescue monotherapy with adefovir (ADV) in patients with chronic hepatitis B (CHB) who developed drug resistance to lamivudine (LAM). METHODS: A total of 76 treated CHB patients with resistance to LAM were enrolled in the present study. The patients' baseline characteristics, such as age, gender, blood tests and hepatitis B virus (HBV) DNA were collected; therapy duration and the response of each patient were also recorded. ADV monotherapy was set as the observation group A. Twenty-four patients with LAM resistance, who were set as group B, accepted combined therapy with LAM + ADV. Patients were followed up at 0, 12, 24, 52, 104 and 156 wk. Hepatitis B surface antigen status, hepatitis B e antigen (HBeAg)/anti-HBe status, HBV DNA level and biochemical indexes were monitored. Sequencer of HBV polymerase gene was performed on the ABI 3730 automated sequencer. If no desired effects had been achieved during the course of treatment, patients' choices were also taken into account. The control group was tested at the same time. RESULTS: In the two groups, 27 cases developed viral breakthrough after LAM treatment response. The remaining 49 cases underwent biochemical rebound accompanied by rtM204I/V or rtL180M mutation. In group A, 52 cases finished 156 wk of ADV monotherapy; of whom, 36 cases were HBeAg positive and 16 HBeAg negative. In patients whose baseline HBV DNAs were 10(3)-10(5) copies/mL, 88.8% of patients' HBV DNAs were lower than the lower test limit (10(3) copies/mL) after 12 to 156 wk of ADV treatment. In patients whose baseline HBV DNAs were ≥ 10(6) copies/mL, 41.1%-47.0% of patients' HBV DNAs were lower than the lower test limit after the same course of ADV therapy (χ(2) were 4.35-5.4, 41.1%-47.0% vs 88.8% group 10(3)-10(5) copies/mL, P < 0.01). In group A, seroconversion of HBeAg developed in 8 of 36 cases (22.2%). In group B, 24 cases finished 156 wk of LAM + ADV; of whom, 17 cases were HBeAg positive and 7 HBeAg negative. In patients whose baseline HBV DNAs were 10(3)-10(5) copies /mL, 81.8% of patients' HBV DNAs were lower than the lower test limit (10(3) copies/mL) after 12 to 156 wk of treatment. In the patients whose baseline HBV DNAs were ≥ 10(6) copies/mL, 46.1%-53.8% of patients' HBV DNAs were lower than the lower test limit after the same course of LAM + ADV therapy (χ(2) were 4.1-5.0, 46.1%-53.8% vs 81.8% group 10(3)-10(5) copies/mL, P < 0.05-0.01). In group B, 4 of 17 cases (23.5%) developed seroconversion of HBeAg. Treatment outcomes in groups A and B were comparable. CONCLUSION: In both group A and B, the ratios of virological response have similar efficacy in patients with lower baseline HBV DNAs.

6.
J Pharm Anal ; 1(2): 113-118, 2011 May.
Article in English | MEDLINE | ID: mdl-29403689

ABSTRACT

A high-Performance liquid chromatography coupled ultraviolet (HPLC-UV) method was developed for a chemical fingerprint analysis of Viscum coloratum. Eighteen peaks were selected as the common peaks and Homoeriodictyol-7-0-ß-D-apiosiyl-(1→2)-ß-D-glucoside was used as a reference. The relative areas of common peaks were used for hierarchical clustering analysis and similarity calculation. Thirty-seven samples collected from different sources were classified into five groups. The similarities of 21 batches Viscum coloratum samples were beyond 0.90. The results obtained suggest that the Chromatographie fingerprint can efficiently identify Viscum coloratum. Additionally, the fingerprints can then be used to evaluate the correlation between Viscum coloratum and hosts.

SELECTION OF CITATIONS
SEARCH DETAIL
...